SNOWFLAKE & THE EVIDENCE CLOUD Towards a radically more collaborative approach to driving patient outcomesTHE EVIDENCE CLOUD 2 CAN WE PUT A VALUE ON A HEALTHIER SOCIETY? One market mechanism to reconcile the divergence between industry cost structures and affordability regulation is the value-based agreement, in which healthcare providers and pharmaceutical manufacturers’ receive payment tied to successful patient outcomes. In the US, the Biden administration has proposed to continue the Centers of Medicare & Medicaid Services’ progress towards value-based payments 1 . In a recent report sponsored by AstraZeneca, such value-based arrangements between payers and biopharmaceutical manufacturers are estimated to potentially generate $36 billion of healthcare cost savings in the

Join for free to read